Economic Evaluation of Bevacizumab Versus Ranibizumab in Neovascular Age-Related Macular Degeneration in China

Economic and Quality of Life Benefits of Anti-VEGF Therapy

“…35 AMD is the leading cause of blindness in Shanghai, and anti-VEGF agents have been widely introduced for the treatment of patients with neovascular retinopathy after bevacizumab was proven effective in reducing macular edema in central retinal vein occlusions and inhibiting CNV in 2006. Li et al 36 reported that ranibizumab for neovascular AMD patients gained similar QALY at significantly higher costs in comparison with bevacizumab in China. Patients on ranibizumab treatment obtained 0.007 QALY more than patients on bevacizumab treatment, while the average total cost was CNY 794,400 higher.…”